Abstract
SUMMARY: Chimeric antigen receptor T-cell therapy is an exciting and rapidly emerging “fifth pillar” treatment for hematologic cancers. Unique treatment-related toxicities and cost remain a major hindrance to its widespread application. The commonly faced challenges with this innovative therapy, its neurotoxicity, and manifestation on neuroimaging studies, are reviewed.
ABBREVIATIONS:
- CAR
- chimeric antigen receptor
- CRS
- cytokine release syndrome
- CRES
- CAR-T-cell–related encephalopathy syndrome
- © 2019 by American Journal of Neuroradiology
Jump to section
- Article
- Abstract
- ABBREVIATIONS:
- What are Chimeric Antigen Receptor T-Cells?
- Who Benefits from CAR T-Cell Therapy?
- How Is CAR T-Cell Therapy Delivered to Patients?
- What Are the Major Toxicities of CAR T-Cell Therapy and How Are They Graded?
- What Are the Neuroradiologic Findings in Patients Receiving CAR T-Cell Therapy?
- What are the Neuroradiologic Recommendations in Patients Receiving CAR T-Cell Therapy?
- What Are the Challenges in Implementing CAR T-Cell Therapy?
- REFERENCES
- Info & Metrics
- Responses
- References